FIELD: medicine.
SUBSTANCE: invention relates to methods of treating a human suffering or susceptible to C3-glomerulopathy, comprising administering to a human an effective amount of a C5aR antagonist.
EFFECT: method of treating C3-glomerulopathy is proposed.
32 cl, 2 ex, 2 tbl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY WITH A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | 2018 |
|
RU2796863C2 |
| N-9-SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | 2010 |
|
RU2607635C2 |
| HUMAN CYTOCHROME 11B2 INHIBITORS | 2022 |
|
RU2800378C1 |
| 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E-SYNTHASE INHIBITORS | 2015 |
|
RU2732416C2 |
| COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | 2012 |
|
RU2606128C2 |
| QUINAZOLINE DERIVATIVES | 2004 |
|
RU2356896C2 |
| 1,3,5-TRIAZINE DERIVATIVE AND A METHOD FOR USE THEREOF | 2016 |
|
RU2724333C2 |
| 5-SUBSTITUTED ALKYLAMINOPYRAZOLE DERIVATIVES AS PESTICIDES | 2003 |
|
RU2308452C2 |
| DERIVATIVES OF TETRAHYDROISOQUINOLINE, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF, METHOD FOR INHIBITION OF SYNAPTIC UPTAKE OF DOPAMINE AND TREATMENT METHOD | 2000 |
|
RU2293728C2 |
| COMBINATION THERAPY USING CC CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE CHECKPOINT INHIBITORS | 2019 |
|
RU2810717C2 |
